G
Guido Moll
Researcher at Charité
Publications - 40
Citations - 3889
Guido Moll is an academic researcher from Charité. The author has contributed to research in topics: Mesenchymal stem cell & Stromal cell. The author has an hindex of 25, co-authored 40 publications receiving 2894 citations. Previous affiliations of Guido Moll include Karolinska Institutet & QIMR Berghofer Medical Research Institute.
Papers
More filters
Journal ArticleDOI
Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation.
L. von Bahr,I. Batsis,Guido Moll,M. Hägg,A. Szakos,Berit Sundberg,Mehmet Uzunel,O Ringdén,K. Le Blanc +8 more
TL;DR: It is concluded that MSCs appear to mediate their function through a “hit and run” mechanism, and the lack of sustained engraftment limits the long‐term risks of MSC therapy.
Journal ArticleDOI
Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study.
Philipp Jungebluth,Philipp Jungebluth,Evren Alici,Silvia Baiguera,Pontus Blomberg,Béla Bozóky,Claire Crowley,Oskar Einarsson,Tomas Gudbjartsson,Sylvie Le Guyader,Gert Henriksson,Ola Hermanson,Jan Erik Juto,Bertil Leidner,Bertil Leidner,Tobias Lilja,Jan Liska,Tom Luedde,Vanessa Lundin,Guido Moll,Christoph Roderburg,Staffan Strömblad,Tolga Sutlu,Emma Watz,Emma Watz,Alexander M. Seifalian,Paolo Macchiarini,Paolo Macchiarini +27 more
TL;DR: These findings, together with increased levels of regenerative-associated plasma factors, strongly suggest stem-cell homing and cell-mediated wound repair, extracellular matrix remodelling, and neovascularisation of the graft are key factors for successful clinical outcome.
Journal ArticleDOI
Do Cryopreserved Mesenchymal Stromal Cells Display Impaired Immunomodulatory and Therapeutic Properties
Guido Moll,Jessica J. Alm,Lindsay C. Davies,Lena von Bahr,Nina Heldring,Lillemor Stenbeck-Funke,Osama A. Hamad,Robin Hinsch,Lech Ignatowicz,Matthew Locke,Helena Lönnies,John D. Lambris,Yuji Teramura,Kristina Nilsson-Ekdahl,Bo Nilsson,Katarina Le Blanc +15 more
TL;DR: Cryobanked MSCs have reduced immunomodulatory and blood regulatory properties directly after thawing, resulting in faster complement‐mediated elimination after blood exposure, paired by differences in therapeutic efficacy in treatment of immune ailments after hematopoietic stem cell transplantation.
Journal ArticleDOI
Are therapeutic human mesenchymal stromal cells compatible with human blood
Guido Moll,Ida Rasmusson-Duprez,Lena von Bahr,Lena von Bahr,Anne-Marie Connolly-Andersen,Anne-Marie Connolly-Andersen,Graciela Elgue,Lillemor Funke,Osama A. Hamad,Helena Lönnies,Peetra U. Magnusson,Javier Sanchez,Yuji Teramura,Kristina Nilsson-Ekdahl,Olle Ringdén,Olle Korsgren,Bo Nilsson,Katarina Le Blanc,Katarina Le Blanc +18 more
TL;DR: It is found that MSCs expressed hemostatic regulators similar to those produced by endothelial cells but displayed higher amounts of prothrombotic tissue/stromal factors on their surface, which triggered the IBMIR after blood exposure, as characterized by formation of blood activation markers.
Journal ArticleDOI
Therapeutic Applications of Mesenchymal Stromal Cells: Paracrine Effects and Potential Improvements
TL;DR: This review will first discuss the hematopoietic stem cell niche, in which MSCs were recently identified and are thought to play an instructive and supportive role, and evaluate therapeutic applications that currently try to utilize the trophic and/or immunomodulatory properties of M SCs.